Lupin FY26 Net Profit Rises 60% to ₹63.7B

Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, and recommended a dividend of ₹18 per share.
Standalone net profit for FY26 increased to ₹63,665.6 million from ₹39,729.6 million in FY25, with revenue growing to ₹195,126.6 million.
Exceptional items included antitrust litigation provisions, settlement payments, and gains from business divestments, significantly impacting quarterly results.
The company completed acquisitions of VISUfarma and Renascience Pharma and transferred OTC and API R&D businesses to subsidiaries.